Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Luis M.A. Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A. Lashuel; David Sulzer; Kostas Vekrellis; Glenda M. Halliday; Julianna J. Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D. Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F. Outeiro

doi:10.1038/s41531-021-00203-9

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Luis M.A. Oliveira^*, Thomas Gasser, Robert Edwards, Markus Zweckstetter, Ronald Melki, Leonidas Stefanis, Hilal A. Lashuel, David Sulzer, Kostas Vekrellis, Glenda M. Halliday, Julianna J. Tomlinson, Michael Schlossmacher, Poul Henning Jensen, Julia Schulze-Hentrich, Olaf Riess, Warren D. Hirst, Omar El-Agnaf, Brit Mollenhauer, Peter Lansbury, Tiago F. Outeiro^*

^*Corresponding author for this work

QBRI - Neurological Disorders Research Center

Research output: Contribution to journal › Review article › peer-review

90 Citations (Scopus)

Abstract

With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.

Original language	English
Article number	65
Journal	npj Parkinson's Disease
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41531-021-00203-9
Publication status	Published - Dec 2021

Access to Document

10.1038/s41531-021-00203-9

Cite this

Oliveira, L. M. A., Gasser, T., Edwards, R., Zweckstetter, M., Melki, R., Stefanis, L., Lashuel, H. A., Sulzer, D., Vekrellis, K., Halliday, G. M., Tomlinson, J. J., Schlossmacher, M., Jensen, P. H., Schulze-Hentrich, J., Riess, O., Hirst, W. D., El-Agnaf, O., Mollenhauer, B., Lansbury, P., & Outeiro, T. F. (2021). Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease. npj Parkinson's Disease, 7(1), Article 65. https://doi.org/10.1038/s41531-021-00203-9

@article{f99c8cb71b4a449da0e4d2266fbe3496,

title = "Alpha-synuclein research: defining strategic moves in the battle against Parkinson{\textquoteright}s disease",

abstract = "With the advent of the genetic era in Parkinson{\textquoteright}s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein{\textquoteright}s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.",

author = "Oliveira, {Luis M.A.} and Thomas Gasser and Robert Edwards and Markus Zweckstetter and Ronald Melki and Leonidas Stefanis and Lashuel, {Hilal A.} and David Sulzer and Kostas Vekrellis and Halliday, {Glenda M.} and Tomlinson, {Julianna J.} and Michael Schlossmacher and Jensen, {Poul Henning} and Julia Schulze-Hentrich and Olaf Riess and Hirst, {Warren D.} and Omar El-Agnaf and Brit Mollenhauer and Peter Lansbury and Outeiro, {Tiago F.}",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1038/s41531-021-00203-9",

language = "English",

volume = "7",

journal = "npj Parkinson's Disease",

issn = "2373-8057",

publisher = "Springer Nature",

number = "1",

}

Oliveira, LMA, Gasser, T, Edwards, R, Zweckstetter, M, Melki, R, Stefanis, L, Lashuel, HA, Sulzer, D, Vekrellis, K, Halliday, GM, Tomlinson, JJ, Schlossmacher, M, Jensen, PH, Schulze-Hentrich, J, Riess, O, Hirst, WD, El-Agnaf, O, Mollenhauer, B, Lansbury, P & Outeiro, TF 2021, 'Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease', npj Parkinson's Disease, vol. 7, no. 1, 65. https://doi.org/10.1038/s41531-021-00203-9

TY - JOUR

T1 - Alpha-synuclein research

T2 - defining strategic moves in the battle against Parkinson’s disease

AU - Oliveira, Luis M.A.

AU - Gasser, Thomas

AU - Edwards, Robert

AU - Zweckstetter, Markus

AU - Melki, Ronald

AU - Stefanis, Leonidas

AU - Lashuel, Hilal A.

AU - Sulzer, David

AU - Vekrellis, Kostas

AU - Halliday, Glenda M.

AU - Tomlinson, Julianna J.

AU - Schlossmacher, Michael

AU - Jensen, Poul Henning

AU - Schulze-Hentrich, Julia

AU - Riess, Olaf

AU - Hirst, Warren D.

AU - El-Agnaf, Omar

AU - Mollenhauer, Brit

AU - Lansbury, Peter

AU - Outeiro, Tiago F.

PY - 2021/12

Y1 - 2021/12

N2 - With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.

AB - With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.

UR - http://www.scopus.com/inward/record.url?scp=85111678889&partnerID=8YFLogxK

U2 - 10.1038/s41531-021-00203-9

DO - 10.1038/s41531-021-00203-9

M3 - Review article

AN - SCOPUS:85111678889

SN - 2373-8057

VL - 7

JO - npj Parkinson's Disease

JF - npj Parkinson's Disease

IS - 1

M1 - 65

ER -

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease

Abstract

Access to Document

Other files and links

Fingerprint

Cite this